Recent Updates
Recently added Catalysts
STRO Positive Sentiment

Sutro Biopharma to Participate in Upcoming Investor Conferences

Key Takeaway: Sutro Biopharma announced its participation in several upcoming investor conferences, including the Stifel Healthcare Conference and the Jefferies Global Healthcare Conference. These events will take place in New York and London throughout November and December 2026. The company focuses on developing innovative antibody-drug conjugates for cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Sutro Biopharma is participating in multiple investor conferences.
  • The company is advancing a next-generation ADC platform.
  • Sutro aims to improve cancer therapies with its innovative approach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
9.8%
average across 5 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
STRO-004
Phase 1 · Head and Neck Squamous Cell Carcinoma HNSCC

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Details of the Company’s participation are as follows:

Stifel Healthcare Conference Fireside Chat Date/Time: November 11 at 8:00 AM EST Location: New York, NY

Truist Securities Biopharma Symposium Date: November 12 Location: New York, NY

UBS Global Biopharma Conference Fireside Chat Date/Time: November 17 at 10:40 AM GMT Location: London, UK

Jefferies Global Healthcare Conference Fireside Chat Date/Time: November 18 at 1:30 PM GMT Location: London, UK

Piper Sandler 38th Annual Healthcare Conference Fireside Chat Date/Time: December 2 at 1:30 PM EST Location: New York, NY

Where available, live webcasts of the presentations can be accessed on the Events & Presentations page in the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will remain available for at least 30 days following each event.
About Sutro Biopharma Sutro Biopharma, Inc. is a clinical-stage biotechnology company advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Investor Contact Emily White Sutro Biopharma (650) 823-7681 ewhite@sutrobio.com

Media Contact Amy Bonanno Lyra Strategic Advisory abonanno@lyraadvisory.com

Frequently Asked Questions

When is Sutro Biopharma participating in investor conferences?

Sutro Biopharma will participate in conferences from November 11 to December 2, 2026.

Where will the conferences take place?

The conferences will be held in New York and London.

What is Sutro Biopharma's focus area?

Sutro focuses on developing antibody-drug conjugates for cancer treatment.

How can I access the conference presentations?

Live webcasts will be available on Sutro's Investor Relations page.

Last updated: Nov 4, 2026